Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.

Authors: Ooi, Aikseng

Published In Semin Cancer Biol, (2020 04)

Abstract: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is an autosomal dominant hereditary cancer syndrome with incomplete penetrance. It is caused by a germline amorphic allele of the FH gene, which encodes the TCA cycle enzyme, fumarate hydratase (FH). HLRCC patients are genetically predisposed to develop skin leiomyomas, uterine fibroids, and the aggressive kidney cancer of type 2 papillary morphology. Loss-of-heterozygocity at the FH locus that cause a complete loss of FH enzymatic function is always detected in these tumor tissues. Molecular pathway elucidation, genomic studies, and systematic genetics screens reported over the last two decades have identified several FH-inactivation driven pathways alterations, as well as rationally conceived treatment strategies that specifically target FH-/- tumor cells. These treatment strategies include ferroptosis induction, oxidative stress promotion, and metabolic alteration. As the fundamental biology of HLRCC continues to be uncovered, these treatment strategies continue to be refined and may one day lead to a strategy to prevent disease onset among HLRCC patients. With a more complete picture of HLRCC biology, the safe translation of experimental treatment strategies into clinical practice is achievable in the foreseeable future.

PubMed ID: 31689495 Exiting the NIEHS site

MeSH Terms: Biomarkers, Tumor; Disease Management; Disease Susceptibility; Fumarate Hydratase/genetics; Genes, Tumor Suppressor; Genetic Predisposition to Disease; Genetic Testing; Genomics/methods; Humans; Hypoxia-Inducible Factor 1, alpha Subunit/genetics; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism; Leiomyomatosis/diagnosis; Leiomyomatosis/etiology*; Leiomyomatosis/metabolism; Leiomyomatosis/therapy; Mutation; Neoplastic Syndromes, Hereditary/diagnosis; Neoplastic Syndromes, Hereditary/etiology*; Neoplastic Syndromes, Hereditary/metabolism; Neoplastic Syndromes, Hereditary/therapy; Proteome; Signal Transduction; Skin Neoplasms/diagnosis; Skin Neoplasms/etiology*; Skin Neoplasms/metabolism; Skin Neoplasms/therapy; Translational Medical Research; Uterine Neoplasms/diagnosis; Uterine Neoplasms/etiology*; Uterine Neoplasms/metabolism; Uterine Neoplasms/therapy

Back
to Top